Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing erythropoietin therapy.

I C Macdougall1

  • 1Department of Renal Medicine, King's College Hospital, London, UK.

Current Opinion in Hematology
|May 5, 1999
PubMed
Summary
This summary is machine-generated.

Optimizing erythropoietin therapy involves using the subcutaneous route for lower doses, twice to thrice weekly. Intravenous iron and other supplements enhance response, while factors like underdialysis and ACE inhibitors are under investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The association between iron deficiency and outcomes: a secondary analysis of the intravenous iron therapy to treat iron deficiency anaemia in patients undergoing major abdominal surgery (PREVENTT) trial.

Anaesthesia·2022
Same author

Prophylactic Ureteric Stents in Renal Transplant Recipients: A Multicenter Randomized Controlled Trial of Early Versus Late Removal.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Iron metabolism, hepcidin, and anemia in orthotopic heart transplantation recipients treated with mammalian target of rapamycin.

Transplantation proceedings·2013
Same author

Hemojuvelin and iron metabolism in kidney and heart allograft recipients.

Transplantation proceedings·2013
Same author

Original articles: increased platelet volume in patients with adult polycystic kidney disease.

Platelets·2010
Same author

Intercurrent events and comorbid conditions influence hemoglobin level variability in dialysis patients.

Clinical nephrology·2009
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Area of Science:

  • Nephrology
  • Pharmacology
  • Internal Medicine

Background:

  • Erythropoietin therapy is crucial for managing anemia in renal failure.
  • Optimizing its use and cost-effectiveness is a significant clinical challenge.

Purpose of the Study:

  • To review current strategies for optimizing erythropoietin therapy.
  • To discuss factors influencing treatment response and ongoing research areas.

Main Methods:

  • Literature review of studies on erythropoietin administration routes and adjuvant therapies.
  • Analysis of factors affecting erythropoietin response, including co-administered medications and dialysis status.
  • Examination of ongoing multicenter studies on target hemoglobin levels.

Main Results:

Related Experiment Videos

  • Subcutaneous administration allows lower erythropoietin doses compared to intravenous.
  • Intravenous iron significantly enhances erythropoietin response.
  • Adjuvant therapies (ascorbic acid, L-carnitine, etc.) and factors like underdialysis and ACE inhibitors are being investigated for their impact.

Conclusions:

  • Optimized erythropoietin therapy involves appropriate route, dosing, and concomitant intravenous iron.
  • Further research is needed to clarify the role of various adjuvant therapies and influencing factors.
  • Optimal target hemoglobin concentration in renal failure patients remains an area of active investigation.